Long-term Efficacy and Safety, Including COVID-19 Infections, Among Ozanimod-Treated Patients With Relapsing Multiple Sclerosis in the DAYBREAK Open-Label Extension Trial

被引：0

作者：

Cree, B. A. ^{[1
]}

Selmaj, K. W. ^{[2
]}

Steinman, L. ^{[3
]}

Comi, G. ^{[4
]}

Bar-Or, A. ^{[5
]}

Arnold, D. L. ^{[6
]}

Hartung, H. ^{[7
,8
,9
]}

Montalban, X. ^{[10
]}

Havrdova, E. K. ^{[11
,12
]}

Sheffield, J. K. ^{[13
]}

Minton, N. ^{[13
]}

Cheng, C. ^{[13
]}

Silva, D. ^{[13
]}

Kappos, L. ^{[14
,15
,16
,17
,18
]}

Cohen, J. A. ^{[19
]}

机构：

[1] Weill Inst Neurosci, San Francisco, CA USA

[2] Univ Warmia & Mazury, Ctr Neurol & Coll Med, Lodz, Poland

[3] Stanford Univ, Dept Neurol & Neurol Sci, Beckman Ctr Mol Med, Med Ctr, Stanford, CA 94305 USA

[4] Vita Salute San Raffaele Univ & Casa Cura Policli, Milan, Italy

[5] McGill Univ, Philadelphia, PA USA

[6] Montreal Neurol Inst, Neurol & Neurosurg, Montreal, PQ, Canada

[7] Heinrich Heine Univ, Fac Med, Dept Neurol, Dusseldorf, Germany

[8] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia

[9] Med Univ Vienna, Dept Neurol, Dusseldorf, Germany

[10] Hosp Univ Vall dHebron, Dept Neurol Neuroimmunol, Ctr dEsclerosi Multiple Catalunya Cemcat, Barcelona, Spain

[11] Charles Univ Prague, Med Fac 1, Dept Neurol, Prague, Czech Republic

[12] Charles Univ Prague, Med Fac 1, Ctr Clin Neurosci, Prague, Czech Republic

[13] Bristol Myers Squibb, Princeton, NJ USA

[14] Univ Hosp, Dept Med, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland

[15] Univ Hosp, Dept Clin Res, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland

[16] Univ Hosp, Dept Biomed, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland

[17] Univ Hosp, Dept Biomed Engn, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland

[18] Univ Basel, Basel, Switzerland

[19] Cleveland Clin, Mellen Ctr MS Treatment & Res, Cleveland, OH USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 1_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P142

引用

页码：85 / 86

页数：2

共 50 条

[1] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-Or, A.
Arnold, D. L.
Hartung, H. -P.
Montalban, X.
Havrdova, E. K.
Krakovich, A.
Sheffield, J. K.
Cheng, C. -Y.
Minton, N.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 359 - 360
[2] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study
Steinman, L.
Comi, G.
Bar-Or, A.
Selmaj, K. W.
Arnold, D. L.
Hartung, H. -P.
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Minton, N.
Janjua, A.
Huang, V.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 548 - 549
[3] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-Or, A.
Arnold, D. L.
Hartung, H. -P.
Montalban, X.
Havrdova, K.
Hoogerheyde, J.
Afsari, S.
Sheffield, J. K.
Shi, F.
Minton, N.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 617 - 618
[4] Update on Hepatic Safety of Ozanimod in Relapsing Multiple Sclerosis in the DAYBREAK Open-Label Extension Trial
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-Or, A.
Hartung, H. P.
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Thorpe, A.
Riolo, J. V.
Krakovich, A.
Cheng, C. Y.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 325 - 326
[5] COVID-19 infections and vaccinations among patients receiving ozanimod in the daybreak open-label extension trial
Cree, B. A.
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-Or, A.
Arnold, D. L.
Hartung, H. -P.
Montalban, X.
Havrdova, K.
Desai, H.
Sheffield, J. K.
Minton, N.
Cheng, C. -Y.
Silva, D.
Kappos, L.
Cohen, J. A.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 401 - 402
[6] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis in daybreak: an open-label extension study of ozanimod phase 1-3 trials
Selmaj, K.
Steinman, L.
Comi, G.
Bar-Or, A.
Arnold, D.
Hartung, H. P.
Montalban, X.
Havrdova, E.
Sheffield, J.
Chen, T.
Minton, N.
Silva, D.
Kappos, L.
Cohen, J.
Cree, B.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 223 - 223
[7] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
Cree, Bruce A. C.
Selmaj, Krzysztof W.
Steinman, Lawrence
Comi, Giancarlo
Bar-Or, Amit
Arnold, Douglas L.
Hartung, Hans-Peter
Montalban, Xavier
Havrdova, Eva K.
Sheffield, James K.
Minton, Neil
Cheng, Chun-Yen
Silva, Diego
Kappos, Ludwig
Cohen, Jeffrey A.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (12) : 1944 - 1962
[8] Hepatic safety of ozanimod in relapsing multiple sclerosis in the DAYBREAK open-label extension study
Selmaj, K.
Steinman, L.
Comi, G.
Bar-Or, A.
Hartung, H. -P.
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Minton, N.
Afsari, S.
Shi, F.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 608 - 609
[9] Long-term Efficacy of Ozanimod in Relapsing Multiple Sclerosis in DAYBREAK: An Open-Label Extension of the Phase 3 SUNBEAM and RADIANCE Trials
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-or, A.
Arnold, D. L.
Hartung, H-P
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Hetzer, J.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 473 - 474
[10] Predictors of Relapse in Ozanimod-Treated Patients With Multiple Sclerosis: Ad Hoc Analysis From the Open-Label Extension DAYBREAK Study
Coyle, Patricia
Dunn, Jeffrey Dunn Jeffrey
Kappos, Ludwig
Cheng, Chun-Yen
Thorpe, Andrew
Morello, Jean Pierre
Silva, Diego
Filippi, Massimo
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 957 - 958

← 1 2 3 4 5 →